Table 4. Vβ analysis for clonality... | American Society of Hematology

Table 4.

Vβ analysis for clonality assessment in mature T-cell proliferations

Sample	Immunophenotype	Diagnosis	Age, sex	WBC^4-150	% of MNC^4-151	SB analysis	RT-PCR + HD	Sequence analysis of RT−PCR products		Vβ sum	Vβ reactivity of clone
Sample	Immunophenotype	Diagnosis	Age, sex	WBC^4-150	% of MNC^4-151	SB analysis	RT-PCR + HD	Allele 1 (frame)	Allele 2 (frame)	Vβ sum	Vβ reactivity of clone
85-002	CD3/4/2/5	T-PLL	66, F	ND	95%	R/R	Vβ13-Cβ	Vβ13-Jβ2.5 (+)	—	≤5%	no reactivity
86-041	CD3/8/2/5/7	T-LGL	58, F	24.9	95%	R/R	Vβ1-Cβ/Vβ7-Cβ	Vβ1-Jβ2.1 (+)	Vβ7-Jβ1.2 (+)	93%	Vβ1 (90%)
89-068	CD3/4/8/2/7/16neg/56/57	T-LGL	56, M	50.8	55%	R/R	Vβ2-Cβ/Vβ7-Cβ	Vβ2-Jβ2.7 (+)	Vβ7-Jβ1.1 (+)	90%	Vβ2 (60%)
90-008	CD3/4/2/7/16neg/56/57	T-LGL	58, M	10.6	85%	R/R	Vβ6-Cβ	Vβ6-Jβ2.7 (+)	—	13%	no reactivity
91-004	CD3/8/2/7/16neg/56neg	T-CLL	85, F	4.7	90%	R/R	Vβ5-Cβ/Vβ6-Cβ	Vβ5-Jβ2.1 (+)	Vβ6-Jβ1.1 (+)	8%	no reactivity
91-010	CD3/8/2/7/16/57p	T-LGL	46, F	7.7	60%	R/R	Vβ14-Cβ	Vβ14-Jβ1.2 (+)	—	99%	Vβ14 (99%)
91-030	CD3/4/2/5/7/56neg57neg	MF/SS	67, M	13.4	60%	R/R	Vβ5-Cβ	Vβ5-Jβ2.7 (+)	—	67%	Vβ5.2/5.3 (24%) + Vβ22 (10%)³
92-024	CD3/8/2/5/7/57p	T-LGL	55, F	11.3	80%	R/R	Vβ7-Cβ	Vβ7-Jβ1.5 (+)	—	97%	Vβ7.1 (85%)
92-050	CD3/8/2/5/7/57	T-LGL	50, M	7.0	80%	R/R	Vβ23-Cβ	Vβ23-Jβ1.5 (+)	—	95%	Vβ23 (85%)
93-005	CD3/4/2/5/7	T-PLL	75, M	414	98%	R/R	Vβ3-Cβ	Vβ3-Jβ2.1 (+)	—	98%	Vβ3 (94%)
93-026	CD3/8/2/5/7/16neg/ 56neg/57p	T-LGL	66, M	6.5	66%	R/G	Vβ6-Cβ	Vβ6-Jβ2.7 (+)	—	≤5%	no reactivity
93-027	CD3/8/5/7/57p	T-LGL	53, M	ND	80%	R/R	Vβ8-Cβ	Vβ8-Jβ2.5 (+)	—	98%	Vβ8.1/8.2 (90%)
93-067	CD3/4/8/2/7/57p	T-LGL	53, M	6.1	60%	R/R	Vβ3-Cβ/Vβ8-Cβ/ Vβ13-Cβ	Vβ13-Jβ1.1 (+)	Vβ3-Jβ2.1 (+)/ Vβ8-Jβ1.5 (+)	90%	Vβ13.1/13.3 (67%)
93-074	CD3/4/8/5/7	T-CLL	68, F	15.6	25%	R/R	Vβ13-Cβ	Vβ13-Jβ1.1 (+)	—	≤5%	no reactivity
94-058	CD3/4/2/5/7/56neg/57neg	T-CLL	84, np	14.8	65%	R/R	Vβ13-Cβ	Vβ13-Jβ2.2 (+)	—	17%	no reactivity
95-082	CD3/4/2/5/56neg/57neg	SS	50, M	63.2	60%	R/G	Vβ12-Cβ	Vβ12-Jβ1.1 (+)	—	97%	Vβ12.2 (65%)
95-121	CD3/4/8p/16p/56p/57p	T-LGL	75, M	11.8	60%	R/G + R/R	Vβ6-Cβ/Vβ13-Cβ	Vβ6-Jβ2.3 (+)	Vβ13-Jβ1.1 (+)	89%	Vβ13.1/3 (60%) + Vβ6.7 (16%)
95-123	CD3/4/8p/5/7/56neg/57neg	T-NHL	np, M	123	90%	R/R	Vβ8-Cβ	Vβ8-Jβ1.2 (+)	—	98%	Vβ8.1/8.2 (89%)
95-128	Cd3/4/2/5/7	T-CLL	np, np	ND	80%	R/R	Vβ2-Cβ	Vβ2-Jβ2.3 (+)	—	89%	Vβ2 (81%)
95-134	CD3/4/2/5/7	T-PLL	np, np	ND	75%	R/R	Vβ8-Cβ	Vβ8-Jβ2.1 (+)	—	96%	Vβ8.1/8.2 (92%)
95-140	CD3/4/5/7/16neg/56neg/ 57neg	SS	61, M	97.4	83%	R/R	Vβ5-Cβ/Vβ13-Cβ	Vβ13-Jβ2.7 (+)	Vβ5-Jβ2.5 (−)	≤5%	no reactivity
96-013	CD3/8/2/16/57p	T-LGL	58, F	14.3	90%	R/R	Vβ12-Cβ	Vβ12-Jβ2.2 (+)	—	98%	Vβ12.2 (95%)
96-019	CD3/8/2/5/7/57p	T-LGL	62, M	7.7	35%	R/G + R/R	Vβ7-Cβ/Vβ9-Cβ/ Vβ13-Cβ	Vβ7-Jβ1.2 (+)	Vβ9-Jβ2.1 (+)/ Vβ13-Jβ2.1 (+)	12%	no reactivity
96-020	CD3/8/2/5/57p	T-LGL	63, M	6.1	70%	R/R	Vβ5-Cβ/Vβ23-Cβ	Vβ23-Jβ1.4 (+)	Vβ5-Jβ1.1 (−)	95%	Vβ23 (85%)
96-042	CD3/4p/8p/7/56p/57p	T-LGL	45, M	5.5	25%	R/R	Vβ15-Cβ/Vβ16-Cβ	Vβ16-Jβ2.1 (+)	Vβ15-Jβ2.1 (+)	82%	Vβ16 (31%)
96-043	CD3/8/2/5/7/16p/57p	T-LGL	73, F	11.1	85%	R/R	Vβ22-Cβ	Vβ22-Jβ2.6 (+)	—	95%	Vβ22 (90%)
96-049	CD3/4/2/5/7/16neg/ 56neg/57neg	T-CLL	71, M	32.4	85%	R/G	Vβ22-Cβ	Vβ22-Jβ1.1 (+)	—	95%	Vβ22 (94%)
96-050	CD3/8/16/57p	T-LGL	52, F	9.5	15%	R/R	Vβ3-Cβ/Vβ22-Cβ	Vβ3-Jβ1.2 (+)	ND	83%	Vβ3 (20%)
96-067	CD3/8/2/5/16p/57p	T-LGL	39, F	9.0	70%	R/R	Vβ6-Cβ/Vβ19-Cβ	Vβ6-Jβ2.1 (+)	Vβ19-Jβ2.3 (−)	20%	no reactivity
96-154	ND	T-CLL	49, F	6.9	50%	R/R	Vβ7-Cβ/Vβ21-Cβ	Vβ7-Jβ2.5 (+)	ND	8%	no reactivity
97-064	CD3/4p/8p/57p	T-LGL	71, M	1.8	70%	R/R	Vβ13-Cβ	Vβ13-Jβ2.7 (+)	—	14%	no reactivity
97-086	CD3/4/8/57p	T-LGL	45, F	2.2	40%	R/R	Vβ6-Cβ	Vβ6-Jβ2.2 (+)	—	97%^4-153	Vβ6.1 (97%)
97-089	CD3/4/2/5/7	T-PLL	57, M	450	90%	R/R	Vβ7-Cβ/Vβ9-Cβ	Vβ7-Jβ2.6 (+)	Vβ9-Jβ2.5 (+)	10%	no reactivity
97-121	CD3/4/2/5/7	T-NHL	49, F	32.3	80%	R/R	Vβ11-Cβ/Vβ14-Cβ	Vβ14-Jβ2.5 (+)	ND	97%	Vβ14 (93%)
98-002	CD3/4/5/7/16neg/ 56neg/57neg	T-CLL	83, F	59.0	80%	D/R	Vβ7-Cβ	Vβ7-Jβ1.4 (+)	—	≤5%	no reactivity
98-040	CD3/4/2/5/7neg	T-AILD	68, F	18.0	40%	R/R	ND	ND	ND	85%	Vβ17 (53%)
98-047	CD3/4/8/5/7/16neg/ 56neg/57neg	T-CLL	67, M	82.0	95%	R/R	ND	ND	ND	99%	Vβ13.1/13.3 (98%)
98-072	CD3/4/8/2/16neg/ 56neg/57neg	T-CLL	60, M	210	95%	R/R	ND	ND	ND	99%	Vβ2 (99%)
98-080	CD3/4p/2/5/7/16neg/ 56neg/57neg	T-PLL	77, M	NA(LN)	80%	R/R	ND	ND	ND	≤5%	no reactivity
98-086	CD3/4/5/7/16neg/ 56neg/57neg	T-CLL	71, M	158	88%	R/G	Vβ3-Cβ	Vβ3-Jβ1.2 (+)	—	99%	Vβ3 (99%)
98-090	CD3/4/2/5/7	T-PLL	62, F	522	95%	R/R	Vβ1-Cβ/Vβ23-Cβ	Vβ1-Jβ2.3 (+)	ND	99%	Vβ1 (99%)
98-126	CD3/8/2/16/56/57p	T-LGL	73, M	3.3	45%	R/R	Vβ2-Cβ	Vβ2-Jβ1.3 (+)	—	98%	Vβ2 (53%)
98-194	CD3/8/2/7/16-56/57neg	T-LGL	38, F	10.1	90%	R/R	Vβ6-Cβ/Vβ12-Cβ	Vβ6-Jβ1.1 (+)	Vβ12-Jβ2.3 (+)	≤5%	no reactivity
99-100	CD3/8/2/7/16/57	T-LGL	49, M	7.6	75%	R/G	Vβ17-Cβ	Vβ17-Jβ2.7 (+)	—	80%	Vβ17 (66%)
99-125	CD3/8/2/5/7/56neg/57neg	T-PLL	41, M	174	98%	R/R	Vβ3-Cβ	Vβ3-Jβ2.4 (+)	—	99%	Vβ3 (99%)
99-211	CD3/8/2/5/7/16neg/ 56neg/57p	T-LGL	72, F	2.1	85%	R/R	ND	ND	ND	96%	Vβ2 (92%)
99-256	CD3/4/2/5p/7p/16neg/ 56neg/57neg	T-CLL	69, M	17.0	95%	R/R	Vβ13-Cβ	Vβ13-Jβ1.2 (+)	—	≤5%	no reactivity

Sample	Immunophenotype	Diagnosis	Age, sex	WBC^4-150	% of MNC^4-151	SB analysis	RT-PCR + HD	Sequence analysis of RT−PCR products		Vβ sum	Vβ reactivity of clone
Sample	Immunophenotype	Diagnosis	Age, sex	WBC^4-150	% of MNC^4-151	SB analysis	RT-PCR + HD	Allele 1 (frame)	Allele 2 (frame)	Vβ sum	Vβ reactivity of clone
85-002	CD3/4/2/5	T-PLL	66, F	ND	95%	R/R	Vβ13-Cβ	Vβ13-Jβ2.5 (+)	—	≤5%	no reactivity
86-041	CD3/8/2/5/7	T-LGL	58, F	24.9	95%	R/R	Vβ1-Cβ/Vβ7-Cβ	Vβ1-Jβ2.1 (+)	Vβ7-Jβ1.2 (+)	93%	Vβ1 (90%)
89-068	CD3/4/8/2/7/16neg/56/57	T-LGL	56, M	50.8	55%	R/R	Vβ2-Cβ/Vβ7-Cβ	Vβ2-Jβ2.7 (+)	Vβ7-Jβ1.1 (+)	90%	Vβ2 (60%)
90-008	CD3/4/2/7/16neg/56/57	T-LGL	58, M	10.6	85%	R/R	Vβ6-Cβ	Vβ6-Jβ2.7 (+)	—	13%	no reactivity
91-004	CD3/8/2/7/16neg/56neg	T-CLL	85, F	4.7	90%	R/R	Vβ5-Cβ/Vβ6-Cβ	Vβ5-Jβ2.1 (+)	Vβ6-Jβ1.1 (+)	8%	no reactivity
91-010	CD3/8/2/7/16/57p	T-LGL	46, F	7.7	60%	R/R	Vβ14-Cβ	Vβ14-Jβ1.2 (+)	—	99%	Vβ14 (99%)
91-030	CD3/4/2/5/7/56neg57neg	MF/SS	67, M	13.4	60%	R/R	Vβ5-Cβ	Vβ5-Jβ2.7 (+)	—	67%	Vβ5.2/5.3 (24%) + Vβ22 (10%)³
92-024	CD3/8/2/5/7/57p	T-LGL	55, F	11.3	80%	R/R	Vβ7-Cβ	Vβ7-Jβ1.5 (+)	—	97%	Vβ7.1 (85%)
92-050	CD3/8/2/5/7/57	T-LGL	50, M	7.0	80%	R/R	Vβ23-Cβ	Vβ23-Jβ1.5 (+)	—	95%	Vβ23 (85%)
93-005	CD3/4/2/5/7	T-PLL	75, M	414	98%	R/R	Vβ3-Cβ	Vβ3-Jβ2.1 (+)	—	98%	Vβ3 (94%)
93-026	CD3/8/2/5/7/16neg/ 56neg/57p	T-LGL	66, M	6.5	66%	R/G	Vβ6-Cβ	Vβ6-Jβ2.7 (+)	—	≤5%	no reactivity
93-027	CD3/8/5/7/57p	T-LGL	53, M	ND	80%	R/R	Vβ8-Cβ	Vβ8-Jβ2.5 (+)	—	98%	Vβ8.1/8.2 (90%)
93-067	CD3/4/8/2/7/57p	T-LGL	53, M	6.1	60%	R/R	Vβ3-Cβ/Vβ8-Cβ/ Vβ13-Cβ	Vβ13-Jβ1.1 (+)	Vβ3-Jβ2.1 (+)/ Vβ8-Jβ1.5 (+)	90%	Vβ13.1/13.3 (67%)
93-074	CD3/4/8/5/7	T-CLL	68, F	15.6	25%	R/R	Vβ13-Cβ	Vβ13-Jβ1.1 (+)	—	≤5%	no reactivity
94-058	CD3/4/2/5/7/56neg/57neg	T-CLL	84, np	14.8	65%	R/R	Vβ13-Cβ	Vβ13-Jβ2.2 (+)	—	17%	no reactivity
95-082	CD3/4/2/5/56neg/57neg	SS	50, M	63.2	60%	R/G	Vβ12-Cβ	Vβ12-Jβ1.1 (+)	—	97%	Vβ12.2 (65%)
95-121	CD3/4/8p/16p/56p/57p	T-LGL	75, M	11.8	60%	R/G + R/R	Vβ6-Cβ/Vβ13-Cβ	Vβ6-Jβ2.3 (+)	Vβ13-Jβ1.1 (+)	89%	Vβ13.1/3 (60%) + Vβ6.7 (16%)
95-123	CD3/4/8p/5/7/56neg/57neg	T-NHL	np, M	123	90%	R/R	Vβ8-Cβ	Vβ8-Jβ1.2 (+)	—	98%	Vβ8.1/8.2 (89%)
95-128	Cd3/4/2/5/7	T-CLL	np, np	ND	80%	R/R	Vβ2-Cβ	Vβ2-Jβ2.3 (+)	—	89%	Vβ2 (81%)
95-134	CD3/4/2/5/7	T-PLL	np, np	ND	75%	R/R	Vβ8-Cβ	Vβ8-Jβ2.1 (+)	—	96%	Vβ8.1/8.2 (92%)
95-140	CD3/4/5/7/16neg/56neg/ 57neg	SS	61, M	97.4	83%	R/R	Vβ5-Cβ/Vβ13-Cβ	Vβ13-Jβ2.7 (+)	Vβ5-Jβ2.5 (−)	≤5%	no reactivity
96-013	CD3/8/2/16/57p	T-LGL	58, F	14.3	90%	R/R	Vβ12-Cβ	Vβ12-Jβ2.2 (+)	—	98%	Vβ12.2 (95%)
96-019	CD3/8/2/5/7/57p	T-LGL	62, M	7.7	35%	R/G + R/R	Vβ7-Cβ/Vβ9-Cβ/ Vβ13-Cβ	Vβ7-Jβ1.2 (+)	Vβ9-Jβ2.1 (+)/ Vβ13-Jβ2.1 (+)	12%	no reactivity
96-020	CD3/8/2/5/57p	T-LGL	63, M	6.1	70%	R/R	Vβ5-Cβ/Vβ23-Cβ	Vβ23-Jβ1.4 (+)	Vβ5-Jβ1.1 (−)	95%	Vβ23 (85%)
96-042	CD3/4p/8p/7/56p/57p	T-LGL	45, M	5.5	25%	R/R	Vβ15-Cβ/Vβ16-Cβ	Vβ16-Jβ2.1 (+)	Vβ15-Jβ2.1 (+)	82%	Vβ16 (31%)
96-043	CD3/8/2/5/7/16p/57p	T-LGL	73, F	11.1	85%	R/R	Vβ22-Cβ	Vβ22-Jβ2.6 (+)	—	95%	Vβ22 (90%)
96-049	CD3/4/2/5/7/16neg/ 56neg/57neg	T-CLL	71, M	32.4	85%	R/G	Vβ22-Cβ	Vβ22-Jβ1.1 (+)	—	95%	Vβ22 (94%)
96-050	CD3/8/16/57p	T-LGL	52, F	9.5	15%	R/R	Vβ3-Cβ/Vβ22-Cβ	Vβ3-Jβ1.2 (+)	ND	83%	Vβ3 (20%)
96-067	CD3/8/2/5/16p/57p	T-LGL	39, F	9.0	70%	R/R	Vβ6-Cβ/Vβ19-Cβ	Vβ6-Jβ2.1 (+)	Vβ19-Jβ2.3 (−)	20%	no reactivity
96-154	ND	T-CLL	49, F	6.9	50%	R/R	Vβ7-Cβ/Vβ21-Cβ	Vβ7-Jβ2.5 (+)	ND	8%	no reactivity
97-064	CD3/4p/8p/57p	T-LGL	71, M	1.8	70%	R/R	Vβ13-Cβ	Vβ13-Jβ2.7 (+)	—	14%	no reactivity
97-086	CD3/4/8/57p	T-LGL	45, F	2.2	40%	R/R	Vβ6-Cβ	Vβ6-Jβ2.2 (+)	—	97%^4-153	Vβ6.1 (97%)
97-089	CD3/4/2/5/7	T-PLL	57, M	450	90%	R/R	Vβ7-Cβ/Vβ9-Cβ	Vβ7-Jβ2.6 (+)	Vβ9-Jβ2.5 (+)	10%	no reactivity
97-121	CD3/4/2/5/7	T-NHL	49, F	32.3	80%	R/R	Vβ11-Cβ/Vβ14-Cβ	Vβ14-Jβ2.5 (+)	ND	97%	Vβ14 (93%)
98-002	CD3/4/5/7/16neg/ 56neg/57neg	T-CLL	83, F	59.0	80%	D/R	Vβ7-Cβ	Vβ7-Jβ1.4 (+)	—	≤5%	no reactivity
98-040	CD3/4/2/5/7neg	T-AILD	68, F	18.0	40%	R/R	ND	ND	ND	85%	Vβ17 (53%)
98-047	CD3/4/8/5/7/16neg/ 56neg/57neg	T-CLL	67, M	82.0	95%	R/R	ND	ND	ND	99%	Vβ13.1/13.3 (98%)
98-072	CD3/4/8/2/16neg/ 56neg/57neg	T-CLL	60, M	210	95%	R/R	ND	ND	ND	99%	Vβ2 (99%)
98-080	CD3/4p/2/5/7/16neg/ 56neg/57neg	T-PLL	77, M	NA(LN)	80%	R/R	ND	ND	ND	≤5%	no reactivity
98-086	CD3/4/5/7/16neg/ 56neg/57neg	T-CLL	71, M	158	88%	R/G	Vβ3-Cβ	Vβ3-Jβ1.2 (+)	—	99%	Vβ3 (99%)
98-090	CD3/4/2/5/7	T-PLL	62, F	522	95%	R/R	Vβ1-Cβ/Vβ23-Cβ	Vβ1-Jβ2.3 (+)	ND	99%	Vβ1 (99%)
98-126	CD3/8/2/16/56/57p	T-LGL	73, M	3.3	45%	R/R	Vβ2-Cβ	Vβ2-Jβ1.3 (+)	—	98%	Vβ2 (53%)
98-194	CD3/8/2/7/16-56/57neg	T-LGL	38, F	10.1	90%	R/R	Vβ6-Cβ/Vβ12-Cβ	Vβ6-Jβ1.1 (+)	Vβ12-Jβ2.3 (+)	≤5%	no reactivity
99-100	CD3/8/2/7/16/57	T-LGL	49, M	7.6	75%	R/G	Vβ17-Cβ	Vβ17-Jβ2.7 (+)	—	80%	Vβ17 (66%)
99-125	CD3/8/2/5/7/56neg/57neg	T-PLL	41, M	174	98%	R/R	Vβ3-Cβ	Vβ3-Jβ2.4 (+)	—	99%	Vβ3 (99%)
99-211	CD3/8/2/5/7/16neg/ 56neg/57p	T-LGL	72, F	2.1	85%	R/R	ND	ND	ND	96%	Vβ2 (92%)
99-256	CD3/4/2/5p/7p/16neg/ 56neg/57neg	T-CLL	69, M	17.0	95%	R/R	Vβ13-Cβ	Vβ13-Jβ1.2 (+)	—	≤5%	no reactivity

F4-150

WBC given in 10⁹/L.

F4-151

Aberrant cell clone presented as percentage MNC fraction.

‡

Second population probably represents a polyclonal proliferation or a small subclone.

F4-153

Percentage of CD4⁺/CD8⁺ T-cell population.

np indicates not provided; p, partial reactivity.

View Large

This Feature Is Available To Subscribers Only